Nystatin Oral Suspension Articles

1991 "BETTER THAN EXPECTED" AT SCHERING

22 June 1992

DYNAMICS OF THE US ANTIBIOTIC MARKET

22 June 1992

GLAXO RESPONDS TO IMIGRAN ADR REPORTS

22 June 1992

BBG'S NEW CANCER DRUG ENTERS TRIALS

22 June 1992

ECONOMICS AND HEALTH SECTOR ANALYSIS

22 June 1992

launch of new asthma drug

15 June 1992

Sales of drug manufacturers

15 June 1992

EVANS LAUNCHES VIVOTIF IN UK

15 June 1992

ACUVEL ALTERNATIVE FOR PCP TREATMENT?

15 June 1992

ITALY'S RECORDATI LOOKS FOR EXPANSION

15 June 1992

COPROMOTION DEAL FOR ZOVIRAX IN USA

8 June 1992

HORMONE REPLACEMENT THERAPY: US REPORT

8 June 1992

ASTRA TO FUND CMV TREATMENT STUDY

25 May 1992

VITAMIN K1 /CANCER LINK INVESTIGATED

25 May 1992

CORTECS SETS UP IN THE USA

25 May 1992

UK LAUNCH OF MERIEUX' TYPHIM Vi

25 May 1992

DIABETES TREATMENT IN TANZANIA

18 May 1992

NEW DELIVERY SYSTEM FROM ALZA

18 May 1992

FUJISAWA LAUNCHES SELOKEN L IN JAPAN

18 May 1992

"GREAT STRIDES" FOR SCHERING-PLOUGH

18 May 1992

WIDESPREAD IGNORANCE ABOUT HRT IN UK

18 May 1992

TERBINAFINE AND NAIL DERMATOPHYTOSES

11 May 1992

STOCK MARKET COMMENTARY: EUROPE

11 May 1992

UK APPROVAL OF ORAL IMIGRAN

11 May 1992

HOECHST'S TARIVID FOR NF PATIENTS

11 May 1992

CONNAUGHT'S VACCINE RESEARCH PROGRAM

11 May 1992

KEMRON COMES UNDER ATTACK

4 May 1992

NEW ZOVIRAX DATA FOR CHICKENPOX

4 May 1992

SANDOZ' METROGEL LAUNCHED IN UK

27 April 1992

PROJECT REVIEW FROM NOVO NORDISK

27 April 1992

WARNER-LAMBERT'S VIEW TO THE FUTURE

27 April 1992

BELMAC EUROPE LAUNCHES EPO PRODS

27 April 1992

NITRATES: OLD DRUGS, BUT ONES WITH A FUTURE

20 April 1992

STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB

20 April 1992

HUHTAMAKI OPTIMISM FOR 1991 VINDICATED

20 April 1992

IMPROVEMENTS IN 1ST QTR FOR US FIRMS

20 April 1992

CURATEK FILES NDA FOR METROGEL-V

20 April 1992

STOCK MARKET COMMENTARY: EUROPE

13 April 1992

ISRAEL'S YISSUM R&D CO CLAIMS ACHIEVEMENTS

13 April 1992

SAFER TRAVELLER'S DIARRHEA DRUG

13 April 1992

CERVOXAN 60mg LAUNCHED IN FRANCE

13 April 1992

UPJOHN UPDATES ON R&D PROGRESS

13 April 1992

OPTIMISTIC ANALYSIS OF WARNER-LAMBERT

13 April 1992

CERVOXAN 60mg LAUNCHED IN FRANCE

13 April 1992

SAFER TRAVELLER'S DIARRHEA DRUG

13 April 1992

ISRAEL'S YISSUM R&D CO CLAIMS ACHIEVEMENTS

13 April 1992

STOCK MARKET COMMENTARY: EUROPE

6 April 1992

STOCK MARKET COMMENTARY: EUROPE

6 April 1992

PHARMACIST/PATIENT COUNSELLING

23 March 1992

TEN YEARS OF ACE INHIBITION

23 March 1992

ESTRAPAK FOR OSTEOPOROSIS IN UK

23 March 1992

BOEH INGELHEIM CHF DRUG DISCONTINUED

23 March 1992

ADRIA EXTENDS RIFABUTIN IND

23 March 1992

STOCK MARKET COMMENTARY: EUROPE

23 March 1992

DANISH COMPLAIN OVER GLAXO PRICING

23 March 1992

MEDEVA'S ROAD TO SUCCESS

16 March 1992

NEW PRODUCT PHASE FOR BRITISH BIO-TECH

16 March 1992

VARIED FORTUNES FOR COLD REMEDIES

9 March 1992

CORTICOSTEROIDS AND OPTIC NEURITIS

9 March 1992

US GOVT "CONCERN" OVER JAPANESE REG MOVES

9 March 1992

BULLETIN REVIEWS NEW TOPICAL PRODUCTS

9 March 1992

FUJISAWA KOREA JV COMPLETED

9 March 1992

BIOCHEM PHARMA'S JOHN GILLARD

9 March 1992

HAFSLUND NYCOMED 46% OPERATING PROFIT JUMP

17 February 1992

NEW CHEMICAL ENTITIES UPDATE FOR 1991

10 February 1992

US APPROVAL FOR WELLCOME'S MIVACRON

10 February 1992

RECORD 4TH QTR FROM US DRUG COMPANIES

10 February 1992

PROTEUS INTERNATIONAL "PROCEEDING TO PLAN"

3 February 1992

CONNAUGHT PRODS APPROVED IN ASIA

3 February 1992

INDIAN VACCINES VENTURE STALLS

27 January 1992

JAPANESE YEAR-END APPROVALS

27 January 1992

W-L'S PENETREX APPROVED IN USA

27 January 1992

ALZHEIMER'S DISEASE: A GROWING BURDEN

20 January 1992

VIETNAM DRUG PRICING, VACCINES

20 January 1992

SYNTEX "A COMPANY ON THE MOVE"

20 January 1992

ALZA PRODUCT PROMOTIONS

20 January 1992

SB HEP A VACCINE APPROVAL

20 January 1992

STOCK MARKET COMMENTARY: EUROPE

20 January 1992

FORTHCOMING MEETINGS

20 January 1992

FRANCE LOWERS ORAL CONTRACEPTIVE PRICES

13 January 1992

PFIZER'S DIFLUCAN & AIDS-ASSOCIATED CM

13 January 1992

SYNTEX' ORAL TORADOL APPROVED IN USA

13 January 1992

AKZO AFTER 15% of US PILL MARKET

6 January 1992

US MARKET FORECASTS FROM FROST & SULLIVAN

6 January 1992

Axitinib fails pancreatic cancer; Pfizer drops 3.6%

Teva's generic Risperdal cleared in USA

Jan Lundberg tells the Marketletter how AstraZeneca is turning around its pipeline